Zenas BioPharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZBIO | ZYME | ZURA | ZNTL | ZLAB | XNCR | |
|---|---|---|---|---|---|---|
| Market cap | 1.72B | 1.82B | 383.32M | 247.27M | 2.76B | 1.86B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.7 | 24.0 | -5.8 | -1.4 | -11.7 | -7.0 |
| Price/book | 6.8 | 22.5 | 1.9 | 1.3 | 4.5 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +2.71% | +42.41% | +3.63% | +62.96% | −19.98% | +76.43% |
| Today | −3.15% | −1.78% | 0.00% | −4.55% | −1.60% | +1.66% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ZBIO news ›Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma (Nasdaq: ZBIO) presented new obexelimab findings in IgG4-related disease from the Phase 3 INDIGO trial and its extension. The data were presented at the October 8–10, 2026 international symposium in Cambridge,…
Zenas BioPharma Announces Sustained Clinical Activity and Reduced Glucocorticoid Toxicity for Obexelimab in Phase 3 INDIGO IgG4-RD Extension Study
Phase 3 INDIGO findings show obexelimab's sustained activity and reduced glucocorticoid toxicity in IgG4-RD patients. The Phase 3 INDIGO trial showed sustained clinical activity of obexelimab, with fewer patients experiencing…
Zenas BioPharma to Host Virtual R&D Event
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global bioph... Zenas BioPharma to Host Virtual R&D Event WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) --…
Zenas BioPharma announces new data from Phase 3 INDIGO trial on obexelimab
Zenas BioPharma (ZBIO) announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease will be ... Zenas BioPharma announces new data from Phase 3 INDIGO trial on obexelimab Zenas BioPharma…
Zenas BioPharma price target raised to $48 from $41 at Citi
Citi raised the firm’s price target on Zenas BioPharma (ZBIO) to $48 from $41 and keeps a Buy rating on the shares after updating the firm’s obe... Zenas BioPharma price target raised to $48 from $41 at Citi Citi raised the firm’s price…
Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)
In a report released today, from Wedbush maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $45.00. Zenas BioPharma, Inc... In a report released today, from Wedbush maintained a Buy rating on Zenas BioPharma, Inc.,…
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Zenas BioPharma, Inc. (ZBIO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO), Zenas BioPharma, Inc. (ZBIO) and Cartesian Therapeutics (RNAC) with bullish sentiments. Needham analyst Ryan MacDonald reiterated…
H.C. Wainwright Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)
In a report released today, Matthew Caufield from H.C. Wainwright maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $44.00. Caufield covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics,…
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – Longer-term flare protection and safety data from the INDIGO open-label extension will be…
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple...
The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) experts discussing the evolving science and clinical potential of BTK inhibition in progressive MS. Title: BTK Inhibition in MS: An Emerging Approach to…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com8
-
marketscreener.com2
-
seekingalpha.com2
-
globenewswire.com1
-
manilatimes.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.